Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
BIOCHEMICAL AND PHARMACOLOGICAL PROFILE OF A TETRASUBSTITUTED FURANONE AS A HIGHLY SELECTIVE COX-2 INHIBITOR
Autore:
RIENDEAU D; PERCIVAL MD; BOYCE S; BRIDEAU C; CHARLESON S; CROMLISH W; ETHIER D; EVANS J; FALGUEYRET JP; FORDHUTCHINSON AW; GORDON R; GREIG G; GRESSER M; GUAY J; KARGMAN S; LEGER S; MANCINI JA; ONEILL G; OUELLET M; RODGER IW; THERIEN M; WANG Z; WEBB JK; WONG E; XU L; YOUNG RN; ZAMBONI R; PRASIT P; CHAN CC;
Indirizzi:
MERCK FROSST CANADA INC,MERCK FROSST CTR THERAPEUT RES,POB 1005 POINTE CLAIRE PQ H9R 4P8 CANADA MERCK FROSST CTR THERAPEUT RES KIRKLAND PQ H9H 3L1 CANADA MERCK SHARP & DOHME RES LABS,CTR RES NEUROSCI HARLOW CM20 2QR ESSEX ENGLAND
Titolo Testata:
British Journal of Pharmacology
fascicolo: 1, volume: 121, anno: 1997,
pagine: 105 - 117
SICI:
0007-1188(1997)121:1<105:BAPPOA>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROSTAGLANDIN-G/H SYNTHASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ANTI-INFLAMMATORY DRUGS; HUMAN CYCLOOXYGENASE-2; RAT; NS-398; POTENT; AGENT; EXPRESSION; ETODOLAC;
Keywords:
PROSTAGLANDINS; CYCLOOXYGENASE; COX-1; COX-2; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; INFLAMMATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
48
Recensione:
Indirizzi per estratti:
Citazione:
D. Riendeau et al., "BIOCHEMICAL AND PHARMACOLOGICAL PROFILE OF A TETRASUBSTITUTED FURANONE AS A HIGHLY SELECTIVE COX-2 INHIBITOR", British Journal of Pharmacology, 121(1), 1997, pp. 105-117

Abstract

1 DFU henyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furanone) was identified as a novel orally active and highly selective cyclo-oxygenase-2 (COX-2) inhibitor. 2 In CHO cells stably transfected with human COX isozymes, DFU inhibited the arachidonic acid-dependent production of prostaglandin E-2 (PGE(2)) with at least a 1,000 fold selectivity for COX-2 (IC50=41+/-14 nM) over COX-1 (IC50 > 50 mu M). Indomethacin was a potent inhibitor of both COX-1 (IC50=18+/-3 nM and COX-2 (IC50=26+/-6 nM) under the same assay conditions. The large increase in selectivity of DFU over indomethacin was also observed in COX-1 mediated production of thromboxane B-2 (TXB2) by Ca2+ ionophore-challenged human platelets (IC50>50 mu M and 4.1+/-1.7 nM, respectively). 3 DFU caused a time-dependent inhibition of purified recombinant human COX-2 with a K-i valueof 140+/-68 mu M for the initial reversible binding to enzyme and a k(2) value of 0.11+/-0.06 s(-1) for the first order rate constant for formation of a tightly bound enzyme-inhibitor complex. Comparable values of 62+/-26 mu M and 0.06+/-0.01 s(-1) respectively, were obtained for indomethacin. The enzyme-inhibitor complex was found to have 1:1 stoichiometry and to dissociate only very slowly (t(1/2)=1-3 h) with recovery of intact inhibitor and active enzyme. The time-dependent inhibition by DFU was decreased by co-incubation with arachidonic acid under non-turnover conditions, consistent with reversible competitive inhibition at the COX active site. 4 Inhibition of purified recombinant human COX-1 by DFU was very weak and observed only at low concentrations of substrate (IC50=63+/-5 mu M at 0.1 mu M arachidonic acid). In contrast to COX-2, inhibition was time-independent and rapidly reversible. These data are consistent with a reversible competitive inhibition of COX-1. 5 DFU inhibited lipopolysaccharide (LPS)-induced PGE(2) production (COX-2) in a human whole blood assay with a potency (IC50=0.28+/-0.04 mu M) similar to indomethacin (IC50=0.68+/-0.17 mu M). In contrast,DFU was at least 500 times less potent (IC50>97 mu M) than indomethacin at inhibiting coagulation-induced TXB2 production (COX-1) (IC50=0.19+/-0.02 mu M). 6 In a sensitive assay with U937 cell microsomes at a low arachidonic acid concentration (0.1 mu M), DFU inhibited COX-1 with an IC50 value of 13+/-2 mu M as compared to 20+/-1 nM for indomethacin. CGP 28238, etodolac and SC-58125 were about 10 times more potent inhibitors of COX-1 than DFU. The order of potency of various inhibitors was diclofenac>indomethacin similar to naproxen>nimesulide similar to meloxicam similar to piroxicam>NS-398 similar to SC-57666>SC-58125>CGP 28238 similar to etodolac>L-745,337>DFU. 7 DFU inhibited dose-dependently both the carrageenan-induced rat paw oedema (ED50 of 1.1 mg kg(-1) vs 2.0 mg kg(-1) for indomethacin) and hyperalgesia (ED50 of 0.95 mg kg(-1) vs 1.5 mg kg(-1) for indomethacin). The compound was also effective at reversing LPS-induced pyrexia in rats (ED50=0.76 mg kg(-1) vs 1.1 mg kg(-1) for indomethacin). 8 In a sensitive model in which Cr-51 faecal excretion was used to assess the integrity of the gastrointestinal tract in rats, no significant effect was detected after oral administration of DFU (100 mg kg(-1), b.i.d.) for 5 days, whereas chromium leakage was observed with lower doses of diclofenac (3 mg kg(-1)),meloxicam (3 mg kg(-1)) or etodolac (10-30 mg kg(-1)). A 5 day administration of DFU in squirrel monkeys (100 mg kg(-1)) did not affect chromium leakage in contrast to diclofenac (1 mg kg(-1)) or naproxen (5 mg kg(-1)). 9 The results indicate that COX-1 inhibitory effects can bedetected for all selective COX-2 inhibitors tested by use of a sensitive assay at low substrate concentration. The novel inhibitor DFU shows the lowest inhibitory potency against COX-1, a consistent high selectivity of inhibition of COX-2 over COX-1 (>300 fold) with enzyme, whole cell and whole blood assays, with no detectable loss of integrity ofthe gastrointestinal tract at doses >200 fold higher than efficaciousdoses in models of inflammation, pyresis and hyperalgesia. These results provide further evidence that prostanoids derived from COX-1 activity are not important in acute inflammatory responses and that a high therapeutic index of antiinflammatory effect to gastropathy can be achieved with a selective COX-2 inhibitor.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 05:27:05